Search

Your search keyword '"Hiddemann, Wolfgang"' showing total 3,107 results

Search Constraints

Start Over You searched for: Author "Hiddemann, Wolfgang" Remove constraint Author: "Hiddemann, Wolfgang"
3,107 results on '"Hiddemann, Wolfgang"'

Search Results

1. Rituximab, gemcitabine and oxaliplatin in relapsed or refractory indolent and mantle cell lymphoma: results of a multicenter phase I/II-study of the German Low Grade Lymphoma Study Group

2. The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma—a randomized, open-label phase III trial of the European mantle cell lymphoma network

4. Prognostic impact of CEBPA mutational subgroups in adult AML

5. Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG)

6. Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification

8. Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profiles

9. Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study

10. PARP14 is a novel target in STAT6 mutant follicular lymphoma

12. Genomic and microenvironmental landscape of stage I follicular lymphoma, compared with stage III/IV

13. SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma

14. Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation

16. Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study

18. A clinically applicable gene expression–based score predicts resistance to induction treatment in acute myeloid leukemia

19. Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM Study

20. Friday leukemia—a structural phenomenon

21. Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial

22. Single-nucleotide Fcγ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma

24. Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials

25. Prognostic impact of CEBPA mutational subgroups in adult AML

27. Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma

28. Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG)

29. Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia

30. Loss-of-function mutations in the histone methyltransferase EZH2 promote chemotherapy resistance in AML

31. Clinical presentation and differential splicing of SRSF2, U2AF1 and SF3B1 mutations in patients with acute myeloid leukemia

32. The clinical mutatome of core binding factor leukemia

34. Loss of KDM6A confers drug resistance in acute myeloid leukemia

35. The neuropeptide receptor calcitonin receptor-like (CALCRL) is a potential therapeutic target in acute myeloid leukemia

37. A comparison of the prognostic performance of the Lugano 2014 and RECIL 2017 response criteria in patients with NHL from the phase III GOYA and GALLIUM trials

38. P446: COMPREHENSIVE CHARACTERIZATION OF DIFFERENTIAL GENE EXPRESSION AND ISOFORM USAGE IN SPLICING FACTOR-MUTATED ACUTE MYELOID LEUKEMIA USING LONG-READ SEQUENCING

39. P434: MYELODYSPLASIA-RELATED MUTATIONS IN THE NEW ELN CLASSIFICATION: DOES CLONAL SIZE PLAY A ROLE?

40. P457: COMPLEX CARYOTYPE IS AN INDEPENDENT RISK FACTOR IN TP53-MUTATED AML

41. Duodenal-type and nodal follicular lymphomas differ by their immune microenvironment rather than their mutation profiles

46. Acute megakaryoblastic leukaemia shows high frequency of chromosome 1q aberrations and dismal outcome

47. Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study

50. Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia

Catalog

Books, media, physical & digital resources